الفهرس 
ST- Elevation Myocardial InfarctionOnly 14 pages are availabe for public view
 |  | from | 112 |  |  |
| | | from | 112 | | |
Abstract
Worldwide, ischemic heart disease is the single most common cause of death. STEMI is a significant cause of morbidity and mortality in patients with coronary heart disease.
PCI is considered to be the preferred reperfusion strategy for ACS. Despite optimal evidence-based PCI, periprocedural myocardial injury and myocardial no-reflow phenomenon can still occur and are associated with a worse in-hospital and long-term prognosis. Angiographic no-reflow is defined as less than TIMI 3 flow or TIMI 3 flow with MBG 0 or 1 without angiographic evidence of mechanical vessel obstruction.
Statins in addition to its beneficial lipid modulation effects, exerts a variety of several so-called pleiotropic actions such as inhibiting inflammation, anti-ventricular remodeling, improving vascular endothelial function and antioxidant effects.
The value of high intensity statins loading in acute STEMI patients undergoing primary PCI is still a debatable subject. The benefits of statin pre-treatment before PCI have been supported with previous studies for patients with stable angina pectoris and ACS (unstable angina and non-STEMI); however, only a few retrospective studies have evaluated statin pre-treatment in STEMI.